US biotech Gilead Sciences has added two names to its senior leadership team, with Kevin Young taking on the chief operating officer role and Martin Silverstein becoming executive vice president for strategy. 25 May 2016
US drugmaker Ariad Pharmaceuticals has appointed Jennifer Herron as executive vice president, chief commercial officer, effective May 31, 2016. 25 May 2016
UK biotech Silence Therapeutics has announced a number of changes to its management as it positions itself as a leading RNA technology company. 25 May 2016
Olivier Brandicourt, chief executive of French pharma major Sanofi, announced today a number of changes to the company's executive committee. 23 May 2016
UK-based Proteome Sciences has said that Jeremy Haigh will be joining its board of directors as chief executive in June (subject to regulatory approval). 18 May 2016
Novartis late yesterday announced major changes to focus its Pharmaceuticals Division by creating two business units reporting to the chief executive: Novartis Pharmaceuticals and Novartis Oncology. 18 May 2016
Japanese pharma major Takeda Pharmaceutical has appointed James Kehoe as its new chief financial officer (CFO), hailing his ‘passion for transforming large organizations’ as key to the company’s growth ambitions. 16 May 2016
Japanese drug major Astellas has appointed Rodrigo Fernandez executive director, international business, with responsibility for managing business in Latin America outside of Brazil. 29 April 2016
Ireland-based Perrigo has announced that Sharon Kochan will lead the expansion of the company’s branded consumer healthcare (BCH) segment. 28 April 2016
US biotech major Biogen has lured Michael Ehlers, a senior vice president at pharma giant Pfizer, as its executive vice president, Research and Development. 27 April 2016
Troubled Valeant Pharmaceuticals has named Joseph Papa as its new chief executive, calling him an appointment with “an ethical approach.” 25 April 2016
Maya Martinez-Davis has been appointed as global head of oncology of the biopharma business of German pharma giant Merck KGaA, it was announced on Thursday. 14 April 2016
Starboard Value, a privately owned hedge fund sponsor, has written a strongly-worded letter to US specialty drugmaker Depomed, in which the investor now owns almost 10% of the shares. 11 April 2016
US biotech major Biogen has recruited former Merck & Co executive Michel Vounatsos as the company’s executive vice president and chief commercial officer, effective April 18, 2016. 30 March 2016
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024